This bill creates a new statewide regulatory framework called the "psychedelic substances act" that authorizes licensed use of specified psychedelic substances by adults 21 and older and establishes new regulatory chapters in Title 18 and Title 66 RCW. It charges the Department of Health with licensing facilitators, clinical facilitators, associate versions, and service centers and requires the DOH to adopt rules for preparation, administration, integration sessions, authorized locations, training, exams, confidentiality, and quality-of-care standards. The Washington psychedelic substances board is created within the department to advise and assist rulemaking and reporting, and the Liquor and Cannabis Board is assigned a parallel program to license and regulate manufacturers and laboratories, including testing, tracking, labeling, and packaging rules. The bill sets program timelines (rules by October 31, 2027; licensing applications accepted beginning November 1, 2027), a minimum client and licensee age of 21, required pre-session education and post-session integration offerings, and expressly does not require public or private insurers to reimburse for services. The act changes existing law and procedures by adding new licensing schemes, bringing facilitators and clinical facilitators under the Uniform Disciplinary Act and listing disciplinary authorities and procedures, creating dedicated regulation and enforcement accounts, and amending multiple RCWs (including definitions in RCW 69.50.101, public records exemptions in chapter 42.56 RCW, and provisions in chapter 15.130 RCW). It creates civil enforcement tools and penalties: violations of chapter rules are treated as civil infractions (class 2), a false age-identification offense is a class 1 civil infraction, the department or board may impose civil penalties up to $5,000 per violation and laboratories face penalties up to $500 per day for violations. The bill also adds protections from arrest, prosecution, or employment discrimination for health professionals advising patients, clients, caregivers, and service center clients acting in compliance with the chapter, subject to limits such as visible impairment at work and federal contract/grant requirements. Some important operational details are missing or incomplete in the provided text. Section 6 (the complete statutory definition of "psychedelic substance" and terms like "psychedelic harm reduction integration") is not fully included; several rulemaking specifics, fee schedules, exact licensing criteria, portions of the board and department authorities, and the contents of certain sections that are cut off (including sections tied to expiration or delayed effective dates) are not shown here. The summary above is limited to the provisions and references expressly contained in the extracted material.

If enacted, Washington would create a regulated system that allows adults 21 and older to receive guided psychedelic substance sessions while assigning the Department of Health to license and set rules for facilitators and service centers and the Liquor and Cannabis Board to license manufacturers and testing labs. Key deadlines: the state must publish safety information by Dec. 31, 2025, adopt rules by Oct. 31, 2027, and begin accepting license applications Nov. 1, 2027; training, exams (offered at least twice a year), supervised practice hours, preparation and integration sessions, storage, transport, testing, labeling, and packaging requirements are all required under the new framework. Fees for licenses and lab/label preapproval are to cover program costs and go into dedicated state accounts; insurers and public benefit programs are not required to pay for psychedelic administration, and local governments cannot impose taxes or proximity-based bans on licensed operations. The parties most affected will be the Department of Health and the Liquor and Cannabis Board, which take on new regulatory and enforcement responsibilities, and businesses and workers in the new industry—service center operators, facilitators and clinical facilitators, manufacturers, and labs—who will face licensing costs, training and supervised-practice requirements, liability/insurance expectations, testing and labeling compliance, routine inspections, and exposure to civil penalties (up to $5,000 per violation and smaller daily penalties for lab violations). Adults seeking services gain a defined pathway with required education, preparation, and integration supports, and employers face limits on disciplining employees for sanctioned use absent visible impairment. Important implementation details—exact fee amounts, specific testing and training standards, and the precise statutory definitions in section 6—are not included in the provided facts, so the timing, cost levels, and operational specifics will depend on rules the agencies adopt.